Esmolol is used to quickly lower heart rate and blood pressure in patients during surgery or in emergency situations when the heart is beating too fast or irregularly.[2] Brevibloc is currently approved and in use across 23 indications[4].[1]
Brevibloc is one of 444 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
332 competitors in Treatment
Brevibloc
Emtriva
Lamprene
Niclocide
Alfenta
Foscavir
Hivid
Sirturo
Reminyl
Barhemsys
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Aug 15, 1988
BREVIBLOC
NDA NDA019386
Apr 7, 2016
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
NDA NDA205703
Sources